Novartis withdraws marketing application for Ruvise
LONDON (Reuters) - Swiss drugmaker Novartis has withdrawn a marketing application for its drug Ruvise, designed to treat arterial hypertension, the European Medicines Agency (EMA) said on Thursday.
The drug, known generically imatinib mesilate, was intended for use in adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH), the drug regulator said in a statement.
EMA reported that Novartis had said that the withdrawal was because it requires additional data to address the regulator's questions relating to its benefit-risk assessment.
The data would not be available within the timeframe allowed in the centralized procedure, it said.
(Reporting by Kate Kelland; Editing by David Goodman)
- Tweet this
- Share this
- Digg this
- Hungary plans new tax on Internet traffic, public calls for rally
- ECB cools speculation over bank health checks ahead of results
- Bank of England minutes add to signs rate hike on back burner
- Embarrassed Williams suffers humbling defeat
- No Russia-Ukraine gas deal at EU talks; Moscow queries finances |